Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Overview of attention for article published in BMC Medicine, February 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 29 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 16,505 followers.

PubMed_ Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial https://t.co/I95VdUjQ84

01 Feb 2022

Reply Repost Favourite

RT @mlazqui: Efficacy and safety of #pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II tri…

01 Feb 2022

Reply Repost Favourite

Efficacy and safety of #pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial https://t.co/Y1GefDWjNY

01 Feb 2022

Reply Repost Favourite

A multicenter, single-arm, phase II trial studying the efficacy and safety of #pyrotinib in advanced #LungAdenocarcinoma with #HER2 mutations. Read it here: https://t.co/XQnFIzMXlk https://t.co/aygz3VyqZp

01 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.